• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    France Neuropsychiatric Disorders Treatment Market

    ID: MRFR/HC/43515-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    France Neuropsychiatric Disorders Treatment Market Research Report By Type (Degenerative Diseases, Neurotic Disorders, Psychosis, Others), By Application (Shock Treatment, Drug Treatment, Others) and By End User (Hospitals, Clinics, Research Centre’s, Others)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    France Neuropsychiatric Disorders Treatment Market Research Report - Forecast to 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    France Neuropsychiatric Disorders Treatment Market Summary

    The France Neuropsychiatric Disorders Treatment market is projected to grow significantly from 5.22 USD Billion in 2024 to 15.1 USD Billion by 2035.

    Key Market Trends & Highlights

    France Neuropsychiatric Disorders Treatment Key Trends and Highlights

    • The market is expected to expand at a compound annual growth rate (CAGR) of 10.11% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 15.1 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 5.22 USD Billion, reflecting a strong foundation for future expansion.
    • Growing adoption of innovative treatment modalities due to increasing prevalence of neuropsychiatric disorders is a major market driver.

    Market Size & Forecast

    2024 Market Size 5.22 (USD Billion)
    2035 Market Size 15.1 (USD Billion)
    CAGR (2025-2035) 10.11%

    Major Players

    Roche, AstraZeneca, Johnson and Johnson, Sanofi, Otsuka Pharmaceutical, Amgen, Novartis, Merck and Co, Pfizer, GSK, Teva Pharmaceutical Industries, BristolMyers Squibb, H. Lundbeck, AbbVie, Eli Lilly

    France Neuropsychiatric Disorders Treatment Market Trends

    In France, there is significant growth in the treatment market for neuropsychiatric disorders due to the increasing prevalence of mental health issues and an overall rise in awareness of mental health in the country. Some of the healthcare policies aimed at improving mental health services, such as the 2018-2022 Mental Health Roadmap Policy, have integrated them into General healthcare. This resulted in an increased demand for better accessibility and more comprehensive treatment services.

    The introduction of new ways of caring for patients, such as the use of personalized medicine, innovative therapies, digital health solutions, and telepsychiatry, makes these treatments more effective in addressing the current trend.

    Moreover, there are new gaps that can be targeted by marketers of new drugs and biologics with neurostimulation devices in France. There is a growing partnership between private businesses and universities for R&D activities, which may lead to the speedy delivery of new therapies. Putting more emphasis on managing and controlling neuropsychiatric disorders at an early stage signals a drastic change in the way patients will be treated over time. Also, these recent patterns show the demand for more sophisticated care systems that integrate medicine, psychology, and social help is growing.

    France Neuropsychiatric Disorders Treatment Market Drivers

    Market Segment Insights

    Neuropsychiatric Disorders Treatment Market Type Insights

    The France Neuropsychiatric Disorders Treatment Market showcases a diverse array of types, each encompassing a unique set of challenges and treatment modalities. Within this landscape, Degenerative Diseases stand out due to their complex nature, often requiring long-term management strategies and innovative therapeutic approaches. These conditions, which progressively impair cognitive and motor functions, have garnered increasing attention from both healthcare professionals and researchers in the region. Neurotic Disorders, on the other hand, represent a significant portion of the treatment landscape, characterized by symptoms of anxiety and emotional distress, which often demand an integrated approach combining psychotherapy and medication for effective management.

    Psychosis remains a critical focus within the France Neuropsychiatric Disorders Treatment Market, as it affects patients’ perceptions of reality, necessitating comprehensive treatment plans that incorporate antipsychotic medications and psychosocial interventions. The significant public health implications of psychotic disorders make them a priority for mental health services, particularly in urban areas where incidence rates may be higher. Furthermore, the 'Others' category encapsulates a variety of conditions, including mood disorders and substance-related disorders, which collectively require a tailored approach to treatment that recognizes underlying factors and co-morbidities prevalent in the French population.

    Factors such as increasing awareness about mental health, societal stigma reduction, and the availability of advanced treatment options contribute to the overall market growth. The French government has also prioritized mental health, which is evident through various healthcare initiatives aimed at improving access and quality of care. As a result, opportunities abound within each type of segment, prompting ongoing research and development to meet the evolving needs of patients suffering from neuropsychiatric disorders.

    Overall, the complexity and variety within France’s Neuropsychiatric Disorders Treatment Market's Type segmentation underline the necessity for specialized treatments and dedicated healthcare policies to address these multifaceted issues effectively.

    Neuropsychiatric Disorders Treatment Market Application Insights

    The France Neuropsychiatric Disorders Treatment Market, focusing on the Application segment, offers a diverse array of approaches for addressing mental health challenges, including Shock Treatment, Drug Treatment, and others. The significance of Drug Treatment remains prominent, as it is widely utilized to manage conditions such as depression, anxiety, and schizophrenia, providing essential relief for many patients across France.

    Shock Treatment, often associated with Electroconvulsive Therapy (ECT), plays a critical role in providing rapid relief for severe depressive episodes, highlighting its importance in the therapeutic landscape.Other treatment options also contribute to the market's robustness by incorporating various therapeutic techniques aimed at personalizing patient care. The French government's ongoing commitment to mental health initiatives further stimulates market growth and encourages innovation in treatment methodologies. The increasing awareness of neuropsychiatric disorders and the necessity for effective treatment solutions have driven interest in these various applications, leading to research advancements and potential market opportunities moving forward.

    Neuropsychiatric Disorders Treatment Market End User Insights

    The France Neuropsychiatric Disorders Treatment Market is characterized by diverse End User segments, which play significant roles in the effective delivery of treatment. Hospitals often serve as critical access points for patients, providing comprehensive care and specialized services for complex neuropsychiatric conditions. Clinics, with their focused approach, facilitate outpatient treatment and early intervention, catering to individuals seeking accessible care.

    Research Centres contribute to the development of innovative therapies, advancing the understanding of neuropsychiatric disorders and driving market growth through clinical trials and studies.Additionally, other facilities, such as private practices and rehabilitation centers, support the continuum of care and rehabilitation for patients. This segmentation reflects the multifaceted nature of neuropsychiatric treatment in France, highlighting the need for collaboration among different service providers to enhance patient outcomes and address the growing demand for mental health services.

    The evolving landscape of mental health awareness in France further drives the significance of these facilities in ensuring that individuals suffering from neuropsychiatric disorders receive appropriate and timely care.

    Get more detailed insights about France Neuropsychiatric Disorders Treatment Market Research Report - Forecast to 2035

    Request Free Sample

    Regional Insights

    Key Players and Competitive Insights

    The competitive landscape of the France Neuropsychiatric Disorders Treatment Market is characterized by a multitude of players striving to innovate and provide effective treatments for various neuropsychiatric conditions. This market encompasses a range of therapeutic interventions targeting disorders such as depression, anxiety, schizophrenia, and bipolar disorder. With rising awareness of mental health issues and increasing patient populations, pharmaceutical companies are competing aggressively to capture market share, leading to enhanced research and development investments.

    The growing acceptance of neuropsychiatry as a significant field within healthcare has spurred collaborations between biotech firms and universities, alongside the advent of novel drugs and treatment methodologies, which underscores the competitive dynamics at play in the region. Roche stands out in the France Neuropsychiatric Disorders Treatment Market with its strong reputation for developing innovative therapies tailored for neuropsychiatric conditions. The company's solid market presence is buttressed by its commitment to research and development, enabling it to bring advanced treatment options to patients.

    Roche's strengths lie in its robust pipeline that addresses significant unmet needs, allowing it to position itself as a leading player in the treatment domain for neuropsychiatric disorders. Additionally, Roche's well-established collaborations with healthcare professionals and institutions in France enhance its understanding of local patient needs and treatment efficacy, further solidifying its competitive advantage in the market.AstraZeneca holds a significant position within the France Neuropsychiatric Disorders Treatment Market, and it is recognized for its key contributions to the development of therapeutic solutions targeting various mental health disorders.

    The company’s portfolio includes several established products specifically formulated for neuropsychiatric conditions, showcasing AstraZeneca's commitment to addressing the complexities of mental health treatment. The company benefits from a strong presence in the French market, empowered by strategic mergers and acquisitions that have expanded its capabilities and offerings. AstraZeneca's ongoing investments in clinical trials and research not only strengthen its product lineup but also reinforce its reputation as a leader in the field.

    Their robust marketing strategies and partnerships with local healthcare providers foster greater awareness and accessibility of their pharmaceuticals, allowing AstraZeneca to maintain a competitive edge in servicing the neuropsychiatric needs of patients across France.

    Key Companies in the France Neuropsychiatric Disorders Treatment Market market include

    Industry Developments

    Recent developments in the France Neuropsychiatric Disorders Treatment Market reflect ongoing advancements and challenges within the sector. Notably, companies like Roche, AstraZeneca, and Johnson & Johnson are investing in research and development to enhance treatment options for disorders such as depression and anxiety. In April 2023, Amgen announced advancements in their pipeline targeting neurodegenerative diseases, which garnered significant attention in France's health community. Meanwhile, Sanofi's collaboration with Otsuka Pharmaceutical aims to improve medication adherence in patients with schizophrenia, signaling a focus on patient-centric treatment strategies.

    The market has also seen growth in valuations, as Pfizer and GSK report a rise in demand for mental health therapies due to increasing awareness and a heightened focus on mental health post-pandemic. Furthermore, in February 2023, Merck & Co. completed an acquisition of a smaller biotech firm focused on neuropsychiatric treatments, which is expected to strengthen its portfolio in France. Additionally, the French Ministry of Health is launching initiatives to integrate mental health services into primary care, significantly impacting the treatment landscape.

    Market Segmentation

    Outlook

    • Hospitals
    • Clinics
    • Research Centre’s
    • Others

    France Neuropsychiatric Disorders Treatment Market Type Outlook

    • Degenerative Diseases
    • Neurotic Disorders
    • Psychosis
    • Others

    France Neuropsychiatric Disorders Treatment Market End User Outlook

    • Hospitals
    • Clinics
    • Research Centre’s
    • Others

    France Neuropsychiatric Disorders Treatment Market Application Outlook

    • Shock Treatment
    • Drug Treatment
    • Others

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2023 4.74(USD Billion)
    MARKET SIZE 2024 5.22(USD Billion)
    MARKET SIZE 2035 15.06(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 10.107% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Billion
    KEY COMPANIES PROFILED Roche, AstraZeneca, Johnson and Johnson, Sanofi, Otsuka Pharmaceutical, Amgen, Novartis, Merck and Co, Pfizer, GSK, Teva Pharmaceutical Industries, BristolMyers Squibb, H. Lundbeck, AbbVie, Eli Lilly
    SEGMENTS COVERED Type, Application, End User
    KEY MARKET OPPORTUNITIES Aging population increasing treatment demand, Growing awareness of mental health, Advancements in neuropharmaceuticals, Telemedicine for therapy access, Integration of AI in diagnostics
    KEY MARKET DYNAMICS Increasing prevalence of disorders, Growing geriatric population, Advancements in treatment technology, Rising awareness and diagnosis, Expanding healthcare infrastructure
    COUNTRIES COVERED France

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch
    Leave a Comment

    FAQs

    What is the expected market size of the France Neuropsychiatric Disorders Treatment Market in 2024?

    The France Neuropsychiatric Disorders Treatment Market is expected to be valued at 5.22 USD Billion in 2024.

    What is the projected market size in 2035 for the France Neuropsychiatric Disorders Treatment Market?

    By 2035, the France Neuropsychiatric Disorders Treatment Market is projected to reach a value of 15.06 USD Billion.

    What is the expected CAGR for the France Neuropsychiatric Disorders Treatment Market from 2025 to 2035?

    The expected CAGR for the France Neuropsychiatric Disorders Treatment Market from 2025 to 2035 is 10.107%.

    Which segment of the France Neuropsychiatric Disorders Treatment Market is projected to have the highest value in 2035?

    In 2035, the Degenerative Diseases segment is projected to have the highest value at 4.9 USD Billion.

    Who are the key players in the France Neuropsychiatric Disorders Treatment Market?

    Major players in the market include Roche, AstraZeneca, Johnson and Johnson, Sanofi, and Otsuka Pharmaceutical.

    What is the market value for the Neurotic Disorders segment in 2024?

    The Neurotic Disorders segment is valued at 1.4 USD Billion in 2024.

    What challenges does the France Neuropsychiatric Disorders Treatment Market currently face?

    The market currently faces challenges such as rising treatment costs and the need for innovative therapies.

    What is the market value for the Psychosis segment in 2035?

    The Psychosis segment is expected to reach a value of 3.0 USD Billion in 2035.

    What are the growth opportunities in the France Neuropsychiatric Disorders Treatment Market?

    There are growth opportunities in the development of new treatment modalities and personalized medicine.

    How significant is the Others segment expected to be by 2035?

    The Others segment is expected to grow to 3.16 USD Billion by 2035.

    1. \nTable\nof Contents\n\n\n\n\n\n\n\n \n\n\n \n\n\n\t\n\n\tEXECUTIVE\n\tSUMMARY
    2. \ \n\t\n\t\n\t\t\n\n\t\tMarket Overview \n\t\t\n\t\t\n\n\n\t\tKey Findings \n\t\t\n\t\t\n\n\n\t\tMarket Segmentation \n\t\t\n\t\t\n\n\n\t\tCompetitive Landscape \n\t\t\n\t\t\n\n\n\t\tChallenges and Opportunities\n\t\t
    3. \ \n\t\t\n\t\t\n\n\n\t\tFuture Outlook \n\t\t\n\t\n\n\n\n\n\n
    4. \n\n\n \n\n\n\t\n\n\tMARKET\n\tINTRODUCTION \n\t\n\t\n\t\t\n\n\t\tDefinition
    5. \ \n\t\t\n\t\t\n\n\n\t\tScope of the study \n\t\t\n\t\t\n\t\t\t\n\n\t\t\tResearch
    6. Objective \n\t\t\t\n\t\t\t\n\n\n\t\t\tAssumption \n\t\t\t\n\t\t\t\n\n\n\t\t\tLimitations
    7. \ \n\t\t\t\n\t\t\n\n\t\n\n\t\n\n\n\tRESEARCH\n\tMETHODOLOGY
    8. \ \n\t\n\t\n\t\t\n\n\t\tOverview \n\t\t\n\t\t\n\n\n\t\tData
    9. Mining \n\t\t\n\t\t\n\n\n\t\tSecondary Research \n\t\t\n\t\t\n\n\n\t\tPrimary
    10. Research \n\t\t\n\t\t\n\t\t\t\n\n\t\t\tPrimary Interviews and\n\t\t\tInformation
    11. Gathering Process \n\t\t\t\n\t\t\t\n\n\n\t\t\tBreakdown
    12. of Primary\n\t\t\tRespondents \n\t\t\t\n\t\t\n\n\t\t\n\n\n\t\tForecasting
    13. Model \n\t\t\n\t\t\n\n\n\t\tMarket Size Estimation \n\t\t\n\t\t\n\t\t\t\n\n\t\t\tBottom-Up
    14. Approach \n\t\t\t\n\t\t\t\n\n\n\t\t\tTop-Down Approach \n\t\t\t\n\t\t\t\n\t\t\n\n\t\t\n\n\n\t\tData
    15. Triangulation \n\t\t\n\t\t\n\n\n\t\tValidation \n\t\t\n\t\n\n\n\n\n\n
    16. \n\n\n \n\n\n\t\n\n\tMARKET\n\tDYNAMICS \n\t\n\t\n\t\t\n\n\t\tOverview
    17. \ \n\t\t\n\t\t\n\n\n\t\tDrivers \n\t\t\n\t\t\n\n\n\t\tRestraints
    18. \ \n\t\t\n\t\t\n\n\n\t\tOpportunities \n\t\t\n\t\n\n\t\n\n\n\tMARKET\n\tFACTOR
    19. ANALYSIS \n\t\n\t\n\t\t\n\n\t\tValue chain Analysis \n\t\t\n\t\t\n\n\n\t\tPorter's
    20. Five Forces\n\t\tAnalysis \n\t\t\n\t\t\n\t\t\t\n\n\t\t\tBargaining
    21. Power of\n\t\t\tSuppliers \n\t\t\t\n\t\t\t\n\n\n\t\t\tBargaining
    22. Power of Buyers \n\t\t\t \n\t\t\t\n\t\t\t\n\n\n\t\t\tThreat
    23. of New Entrants \n\t\t\t \n\t\t\t\n\t\t\t\n\n\n\t\t\tThreat
    24. of Substitutes \n\t\t\t \n\t\t\t\n\t\t\t\n\n\n\t\t\tIntensity
    25. of Rivalry \n\t\t\t \n\t\t\t\n\t\t\n\n\t\t\n\n\n\t\tCOVID-19
    26. Impact Analysis \n\t\t\n\t\t\n\t\t\t\n\n\t\t\tMarket Impact Analysis
    27. \ \n\t\t\t \n\t\t\t\n\t\t\t\n\n\n\t\t\tRegional Impact \n\t\t\t\n\t\t\t\n\n\n\t\t\tOpportunity
    28. and Threat\n\t\t\tAnalysis \n\t\t\t\n\t\t\n\n\t\n\n\n\n\n\n
    29. \n\n\n \n\n\n\t\n\n\tFrance\n\tNeuropsychiatric Disorders
    30. Treatment Market, BY Type (USD Billion) \n\t\n\t\n\t\n\t\t\n\n\t\tDegenerative
    31. Diseases \n\t\t\n\t\t\n\n\n\t\tNeurotic Disorders \n\t\t\n\t\t\n\n\n\t\tPsychosis
    32. \ \n\t\t\n\t\t\n\n\n\t\tOthers \n\t\t\n\t\n\n\t\n\n\n\tFrance\n\tNeuropsychiatric
    33. Disorders Treatment Market, BY Application (USD\n\tBillion) \n\t\n\t\n\t\t\n\n\t\tShock
    34. Treatment \n\t\t\n\t\t\n\n\n\t\tDrug Treatment \n\t\t\n\t\t\n\n\n\t\tOthers
    35. \ \n\t\t\n\t\n\n\t\n\n\n\tFrance\n\tNeuropsychiatric
    36. Disorders Treatment Market, BY End User (USD\n\tBillion) \n\t\n\t\n\t\t\n\n\t\tHospitals
    37. \ \n\t\t\n\t\t\n\n\n\t\tClinics \n\t\t\n\t\t\n\n\n\t\tResearch
    38. Centre’s \n\t\t\n\t\t\n\n\n\t\tOthers \n\t\t\n\t\n\n\n\n\n\n
    39. \n\n\n \n\n\n\t\n\n\tCompetitive\n\tLandscape \n\t\n\t\n\t\t\n\n\t\tOverview
    40. \ \n\t\t\n\t\t\n\n\n\t\tCompetitive Analysis \n\t\t\n\t\t\n\n\n\t\tMarket
    41. share Analysis \n\t\t\n\t\t\n\n\n\t\tMajor Growth Strategy in
    42. the\n\t\tNeuropsychiatric Disorders Treatment Market \n\t\t\n\t\t\n\n\n\t\tCompetitive
    43. Benchmarking \n\t\t\n\t\t\n\t\t\n\n\n\t\tLeading Players in Terms
    44. of\n\t\tNumber of Developments in the Neuropsychiatric Disorders Treatment\n\t\tMarket
    45. \ \n\t\t\n\t\t\n\n\n\t\tKey developments and growth\n\t\tstrategies
    46. \ \n\t\t\n\t\t\n\t\t\t\n\n\t\t\tNew Product Launch/Service\n\t\t\tDeployment
    47. \ \n\t\t\t\n\t\t\t\n\n\n\t\t\tMerger & Acquisitions \n\t\t\t
    48. \ \n\t\t\t\n\t\t\t\n\n\n\t\t\tJoint Ventures \n\t\t\t\n\t\t\n\n\t\t\n\n\n\t\tMajor
    49. Players Financial\n\t\tMatrix \n\t\t\n\t\t\n\t\t\t\n\n\t\t\tSales
    50. and Operating Income \n\t\t\t \n\t\t\t\n\t\t\t\n\n\n\t\t\tMajor
    51. Players R&D\n\t\t\tExpenditure. 2023 \n\t\t\t\n\t\t\n\n\t\n\n\t\n\n\n\tCompany\n\tProfiles
    52. \ \n\t\n\t\n\t\t\n\n\t\tRoche \n\t\t\n\t\t\n\t\t\t\n\n\t\t\tFinancial
    53. Overview \n\t\t\t\n\t\t\t\n\n\n\t\t\tProducts Offered \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey
    54. Developments \n\t\t\t\n\t\t\t\n\n\n\t\t\tSWOT Analysis \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey
    55. Strategies \n\t\t\t\n\t\t\n\n\t\t\n\n\n\t\tAstraZeneca
    56. \ \n\t\t\n\t\t\n\t\t\t\n\n\t\t\tFinancial Overview \n\t\t\t\n\t\t\t\n\n\n\t\t\tProducts
    57. Offered \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey Developments \n\t\t\t\n\t\t\t\n\n\n\t\t\tSWOT
    58. Analysis \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey Strategies \n\t\t\t\n\t\t\n\n\t\t\n\n\n\t\tJohnson
    59. \ and Johnson \n\t\t\n\t\t\n\t\t\t\n\n\t\t\tFinancial Overview
    60. \ \n\t\t\t\n\t\t\t\n\n\n\t\t\tProducts Offered \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey
    61. Developments \n\t\t\t\n\t\t\t\n\n\n\t\t\tSWOT Analysis \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey
    62. Strategies \n\t\t\t\n\t\t\n\n\t\t\n\n\n\t\tSanofi
    63. \ \n\t\t\n\t\t\n\t\t\t\n\n\t\t\tFinancial Overview \n\t\t\t\n\t\t\t\n\n\n\t\t\tProducts
    64. Offered \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey Developments \n\t\t\t\n\t\t\t\n\n\n\t\t\tSWOT
    65. Analysis \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey Strategies \n\t\t\t\n\t\t\n\n\t\t\n\n\n\t\tOtsuka
    66. Pharmaceutical \n\t\t\n\t\t\n\t\t\t\n\n\t\t\tFinancial Overview
    67. \ \n\t\t\t\n\t\t\t\n\n\n\t\t\tProducts Offered \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey
    68. Developments \n\t\t\t\n\t\t\t\n\n\n\t\t\tSWOT Analysis \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey
    69. Strategies \n\t\t\t\n\t\t\n\n\t\t\n\n\n\t\tAmgen
    70. \ \n\t\t\n\t\t\n\t\t\t\n\n\t\t\tFinancial Overview \n\t\t\t\n\t\t\t\n\n\n\t\t\tProducts
    71. Offered \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey Developments \n\t\t\t\n\t\t\t\n\n\n\t\t\tSWOT
    72. Analysis \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey Strategies \n\t\t\t\n\t\t\n\n\t\t\n\n\n\t\tNovartis
    73. \ \n\t\t\n\t\t\n\t\t\t\n\n\t\t\tFinancial Overview \n\t\t\t\n\t\t\t\n\n\n\t\t\tProducts
    74. Offered \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey Developments \n\t\t\t\n\t\t\t\n\n\n\t\t\tSWOT
    75. Analysis \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey Strategies \n\t\t\t\n\t\t\n\n\t\t\n\n\n\t\tMerck
    76. \ and Co \n\t\t\n\t\t\n\t\t\t\n\n\t\t\tFinancial Overview \n\t\t\t\n\t\t\t\n\n\n\t\t\tProducts
    77. Offered \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey Developments \n\t\t\t\n\t\t\t\n\n\n\t\t\tSWOT
    78. Analysis \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey Strategies \n\t\t\t\n\t\t\n\n\t\t\n\n\n\t\tPfizer
    79. \ \n\t\t\n\t\t\n\t\t\t\n\n\t\t\tFinancial Overview \n\t\t\t\n\t\t\t\n\n\n\t\t\tProducts
    80. Offered \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey Developments \n\t\t\t\n\t\t\t\n\n\n\t\t\tSWOT
    81. Analysis \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey Strategies \n\t\t\t\n\t\t\n\n\t\t\n\n\n\t\tGSK
    82. \ \n\t\t\n\t\t\n\t\t\t\n\n\t\t\tFinancial Overview \n\t\t\t\n\t\t\t\n\n\n\t\t\tProducts
    83. Offered \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey Developments \n\t\t\t\n\t\t\t\n\n\n\t\t\tSWOT
    84. Analysis \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey Strategies \n\t\t\t\n\t\t\n\n\t\t\n\n\n\t\tTeva
    85. Pharmaceutical\n\t\tIndustries \n\t\t\n\t\t\n\t\t\t\n\n\t\t\tFinancial
    86. Overview \n\t\t\t\n\t\t\t\n\n\n\t\t\tProducts Offered \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey
    87. Developments \n\t\t\t\n\t\t\t\n\n\n\t\t\tSWOT Analysis \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey
    88. Strategies \n\t\t\t\n\t\t\n\n\t\t\n\n\n\t\tBristolMyers
    89. Squibb \n\t\t\n\t\t\n\t\t\t\n\n\t\t\tFinancial Overview \n\t\t\t\n\t\t\t\n\n\n\t\t\tProducts
    90. Offered \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey Developments \n\t\t\t\n\t\t\t\n\n\n\t\t\tSWOT
    91. Analysis \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey Strategies \n\t\t\t\n\t\t\n\n\t\t\n\n\n\t\tH.
    92. Lundbeck \n\t\t\n\t\t\n\t\t\t\n\n\t\t\tFinancial Overview \n\t\t\t\n\t\t\t\n\n\n\t\t\tProducts
    93. Offered \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey Developments \n\t\t\t\n\t\t\t\n\n\n\t\t\tSWOT
    94. Analysis \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey Strategies \n\t\t\t\n\t\t\n\n\t\t\n\n\n\t\tAbbVie
    95. \ \n\t\t\n\t\t\n\t\t\t\n\n\t\t\tFinancial Overview \n\t\t\t\n\t\t\t\n\n\n\t\t\tProducts
    96. Offered \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey Developments \n\t\t\t\n\t\t\t\n\n\n\t\t\tSWOT
    97. Analysis \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey Strategies \n\t\t\t\n\t\t\n\n\t\t\n\n\n\t\tEli
    98. Lilly \n\t\t\n\t\t\n\t\t\t\n\n\t\t\tFinancial Overview \n\t\t\t\n\t\t\t\n\n\n\t\t\tProducts
    99. Offered \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey Developments \n\t\t\t\n\t\t\t\n\n\n\t\t\tSWOT
    100. Analysis \n\t\t\t\n\t\t\t\n\n\n\t\t\tKey Strategies \n\t\t\t\n\t\t\t\n\t\t\n\n\t\n\n\t\n\n\n\tAppendix\n\t
    101. \ \n\t\n\t\n\t\t\n\n\t\tReferences \n\t\t\n\t\t\n\n\n\t\tRelated
    102. Reports \n\t\t\n\t\n\n\n\n\nLIST\nOf tables\n\n\n\n\n\n\t\n\n\tLIST\n\tOF
    103. ASSUMPTIONS\n\t \n\t\n\t\n\n\n\tFrance\n\tNeuropsychiatric Disorders
    104. Treatment Market SIZE ESTIMATES &\n\tFORECAST, BY TYPE, 2019-2035 (USD Billions)\n\t
    105. \ \n\t\n\t\n\n\n\tFrance\n\tNeuropsychiatric Disorders Treatment
    106. Market SIZE ESTIMATES &\n\tFORECAST, BY APPLICATION, 2019-2035 (USD Billions)\n\t
    107. \ \n\t\n\t\n\n\n\tFrance\n\tNeuropsychiatric Disorders Treatment
    108. Market SIZE ESTIMATES &\n\tFORECAST, BY END USER, 2019-2035 (USD Billions)\n\t
    109. \ \n\t\n\t\n\n\n\tPRODUCT\n\tLAUNCH/PRODUCT DEVELOPMENT/APPROVAL\n\t
    110. \ \n\t\n\t\n\n\n\tACQUISITION/PARTNERSHIP\n\t \n\t\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nLIST\nOf
    111. DISORDERS TREATMENT MARKET ANALYSIS BY TYPE \n\t\n\t\n\n\n\tFRANCE\n\tNEUROPSYCHIATRIC
    112. DISORDERS TREATMENT MARKET ANALYSIS BY APPLICATION \n\t\n\t\n\n\n\tFRANCE\n\tNEUROPSYCHIATRIC
    113. DISORDERS TREATMENT MARKET ANALYSIS BY END USER \n\t\n\t\n\n\n\tKEY\n\tBUYING
    114. CRITERIA OF NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET \n\t\n\t\n\n\n\tRESEARCH\n\tPROCESS
    115. OF MRFR \n\t\n\t\n\n\n\tDRO\n\tANALYSIS OF NEUROPSYCHIATRIC DISORDERS
    116. TREATMENT MARKET \n\t\n\t\n\n\n\tDRIVERS\n\tIMPACT ANALYSIS: NEUROPSYCHIATRIC
    117. DISORDERS TREATMENT MARKET \n\t\n\t\n\n\n\tRESTRAINTS\n\tIMPACT
    118. ANALYSIS: NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET \n\t\n\t\n\n\n\tSUPPLY\n\t/
    119. VALUE CHAIN: NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET \n\t\n\t\n\n\n\tNEUROPSYCHIATRIC\n\tDISORDERS
    120. TREATMENT MARKET, BY TYPE, 2024 (% SHARE) \n\t\n\t\n\n\n\tNEUROPSYCHIATRIC\n\tDISORDERS
    121. TREATMENT MARKET, BY TYPE, 2019 TO 2035 (USD Billions) \n\t\n\t\n\n\n\tNEUROPSYCHIATRIC\n\tDISORDERS
    122. TREATMENT MARKET, BY APPLICATION, 2024 (% SHARE) \n\t\n\t\n\n\n\tNEUROPSYCHIATRIC\n\tDISORDERS
    123. TREATMENT MARKET, BY APPLICATION, 2019 TO 2035 (USD\n\tBillions) \n\t\n\t\n\n\n\tNEUROPSYCHIATRIC\n\tDISORDERS
    124. TREATMENT MARKET, BY END USER, 2024 (% SHARE) \n\t\n\t\n\n\n\tNEUROPSYCHIATRIC\n\tDISORDERS
    125. TREATMENT MARKET, BY END USER, 2019 TO 2035 (USD Billions)\n\t\n\t\n\t\n\n\n\tBENCHMARKING\n\tOF
    126. MAJOR COMPETITORS \n\t\n\n\n\n\n\n\n\n

    France Neuropsychiatric Disorders Treatment Market Segmentation

    • Neuropsychiatric Disorders Treatment Market By Type (USD Billion, 2019-2035)

      • Degenerative Diseases
      • Neurotic Disorders
      • Psychosis
      • Others

    • Neuropsychiatric Disorders Treatment Market By Application (USD Billion, 2019-2035)

      • Shock Treatment
      • Drug Treatment
      • Others

    • Neuropsychiatric Disorders Treatment Market By End User (USD Billion, 2019-2035)

      • Hospitals
      • Clinics
      • Research Centre’s
      • Others
    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027